Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: A reproducibility study

American Journal of Surgical Pathology

Volumn 35, Issue 12, 2011, Pages 1766-1775

  Visvanathan, Kala ^a,b   Vang, Russell ^b,c   Shaw, Patricia ^d   Gross, Amy ^a   Soslow, Robert ^e   Parkash, Vinita ^a   Shih, Ie Ming ^b,c   Kurman, Robert J ^b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Department of Oncology ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

ovarian cancer; reproducibility; serous tubular intraepithelial carcinoma (STIC)

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ALGORITHM; CARCINOMA IN SITU; CLASSIFICATION; CYSTADENOCARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; OBSERVER VARIATION; OVARY TUMOR; REPRODUCIBILITY; REVIEW; UTERINE TUBE TUMOR;

ALGORITHMS; CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; OBSERVER VARIATION; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 81355127433     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31822f58bc     Document Type: Review

References (16)

1. Blegen H, Einhorn N, Sjovall K, et al. Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. Int J Gynecol Cancer. 2000;10:477-487. (Pubitemid 32066631)
2. Carlson JW, Jarboe EA, Kindelberger D, et al. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol. 2010;29:310-314.
3. Davidson B, Skrede M, Silins I, et al. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer. 2007;110:1264-1271. (Pubitemid 47435597)
4. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1-9. (Pubitemid 351627965)
5. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-443.
6. Lee J, Fung KP. Confidence interval of the kappa coefficient by bootstrap resampling. Psychiatry Res. 1993;49:97-98. (Pubitemid 23329250)
7. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35. (Pubitemid 46092026)
8. Maeda D, Ota S, Takazawa Y, et al. Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases. Virchows Arch. 2010;457:597-608.
9. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236. (Pubitemid 43740193)
10. Mehra K, Mehrad M, Ning G, et al. STICS, SCOUTs and p53 signatures: a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed). 2011;3:625-634.
11. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 2008;110:408-417.
12. Sehdev AS, Kurman RJ, Kuhn E, et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol. 2010;23:844-855.
13. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009;22:1133-1138.
14. Ueda SM, Yap KL, Davidson B, et al. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol. 2010;2010:285191.
15. Wei JJ, Wu J, Luan C, et al. HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol. 2010;34: 18-26.
16. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011 May 6. [Epub ahead of print].